Equities Analysts Offer Predictions for FMS Q1 Earnings

Fresenius Medical Care AG (NYSE:FMS - Free Report) - Investment analysts at Zacks Research lifted their Q1 2025 earnings estimates for Fresenius Medical Care in a research report issued to clients and investors on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay now expects that the company will post earnings per share of $0.44 for the quarter, up from their prior estimate of $0.39. The consensus estimate for Fresenius Medical Care's current full-year earnings is $1.51 per share. Zacks Research also issued estimates for Fresenius Medical Care's Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.56 EPS, FY2025 earnings at $2.01 EPS, Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.49 EPS, Q3 2026 earnings at $0.60 EPS, FY2026 earnings at $2.19 EPS and FY2027 earnings at $2.07 EPS.

Several other equities research analysts have also commented on FMS. StockNews.com upgraded Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. Bank of America upgraded Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a research report on Monday, December 2nd. Finally, Truist Financial lifted their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the company a "hold" rating in a research report on Monday, January 6th.

Remove Ads

Fresenius Medical Care Stock Performance

FMS traded up $0.03 during trading on Thursday, hitting $24.29. The company's stock had a trading volume of 286,196 shares, compared to its average volume of 310,388. The business's 50 day simple moving average is $23.90 and its 200-day simple moving average is $22.42. The firm has a market cap of $14.25 billion, a PE ratio of 20.07, a P/E/G ratio of 0.76 and a beta of 0.99. Fresenius Medical Care has a one year low of $17.93 and a one year high of $25.25. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of FMS. Forum Financial Management LP purchased a new stake in Fresenius Medical Care in the 4th quarter worth $247,000. Vident Advisory LLC boosted its stake in shares of Fresenius Medical Care by 11.8% in the fourth quarter. Vident Advisory LLC now owns 23,410 shares of the company's stock worth $530,000 after acquiring an additional 2,464 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Fresenius Medical Care during the fourth quarter worth about $290,000. Point72 Asset Management L.P. bought a new stake in Fresenius Medical Care during the 4th quarter valued at approximately $850,000. Finally, Quantinno Capital Management LP raised its stake in Fresenius Medical Care by 16.0% during the 4th quarter. Quantinno Capital Management LP now owns 127,726 shares of the company's stock valued at $2,892,000 after purchasing an additional 17,648 shares during the period. Hedge funds and other institutional investors own 8.37% of the company's stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.